drugset
drugset / Trial / NCT05363631

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

NCT05363631 ↗

Phase 1/2 Active not recruiting 55 enrolled Mohammed Milhem University of Iowa · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).

Timeline

Start
2022-09-19
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Selenomethionine Other / unclassified — Oral
Background Axitinib Small molecule — Oral
Background Pembrolizumab Monoclonal antibody — Intravenous

Indications

clear cell renal carcinoma